Advertisement
Original research article| Volume 80, ISSUE 6, P504-511, December 2009

Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial

      Abstract

      Background

      This Phase 3, randomized, open-label, multicenter study conducted at 44 sites in Europe evaluated the safety and efficacy of a continuous, daily regimen of levonorgestrel (LNG) 90 mcg/ethinyl estradiol (EE) 20 mcg compared with a 21-day, cyclic LNG 100 mcg/EE 20 mcg regimen.

      Study Design

      Three hundred twenty-three healthy women were randomized to continuous LNG 90 mcg/EE 20 mcg and 318 subjects to cyclic LNG 100 mcg/EE 20 mcg for 1 year (13 pill packs). Pearl index, adverse event (AE) incidence and bleeding profiles were assessed.

      Results

      No pregnancies occurred with the continuous oral contraceptive (OC) (Pearl index=0.00). As the study progressed, the percentage of women who achieved amenorrhea during each 28-day pill pack increased: 40% at pill pack 7, 53% at pill pack 13. The percentage of women with no bleeding [with or without spotting (defined as not requiring sanitary protection)] was 50%, 69% and 79% at pill packs 3, 7 and 13, respectively. The incidence of AEs was similar to that of the cyclic OC (except for metrorrhagia and vaginal bleeding in the first 6 months).

      Conclusions

      Continuous LNG 90 mcg/EE 20 mcg was shown to be a safe and effective OC in this direct comparison to a cyclic OC. Suppression of menses and the potential for no bleeding requiring sanitary protection may be provided by this continuous, low-dose OC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Loudon N.B.
        • Foxwell M.
        • Potts D.M.
        • Guild A.L.
        • Short R.V.
        Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regiment.
        Br Med J. 1977; 2: 487-490
        • Kovacs G.T.
        • Rusden J.
        • Evans A.
        A trimonthly regimen for oral contraceptives.
        Br J Fam Plann. 1994; 19: 274-275
        • Anderson F.D.
        • Hait H.
        • The Seaonale-301 Study Group
        A multicenter, randomized study of an extended cycle of oral contraceptive.
        Contraception. 2003; 68: 89-96
        • Andrist L.C.
        • Arias R.D.
        • Nucatola D.
        • et al.
        Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives.
        Contraception. 2004; 70: 359-363
        • Wiegratz I.
        • Hommel H.H.
        • Zimmermann T.
        • Kuhl H.
        Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives.
        Contraception. 2004; 69: 37-42
        • den Tonkelaar I.
        • Oddens B.J.
        Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use.
        Contraception. 1999; 59: 357-362
        • Ferrero S.
        • Abbamonte L.H.
        • Giordano M.
        • et al.
        What is the desired menstrual frequency of women without menstruation-related symptoms?.
        Contraception. 2006; 73: 537-541
        • Glasier A.F.
        • Smith K.B.
        • van der Spuy Z.M.
        • et al.
        Amenorrhea associated with contraception — an international study on acceptability.
        Contraception. 2003; 67: 1-8
      1. Archer DF, Kovalevsky G, Ballagh S, Grubb GS. Effect on ovarian activity of a novel levonorgestrel/ethinyl estradiol oral contraceptive regimen. Fertil Steril [Epub ahead of print, May 4, 2009].

        • Belsey E.M.
        • Machin D.
        • d'Arcangues C.
        The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and research training in human reproduction.
        Contraception. 1986; 34: 253-260
      2. U.S. Food and Drug Administration. Depot medroxyprogesterone, summary basis of approval, medical review. October 27, 1992.

        • Jain J.
        • Jakimiuk A.J.
        • Bode F.R.
        • Ross D.
        • Kaunitz A.M.
        Contraceptive efficacy and safety of DMPA-SC.
        Contraception. 2004; 70: 269-275
        • Archer D.F.
        • Jensen J.T.
        • Johnson J.V.
        • Borisute H.
        • Grubb G.S.
        • Constantine G.D.
        Evaluation of a continuous regiment of levonorgestrel/ethinyl estradiol: phase 3 study results.
        Contraception. 2006; 74: 439-445
        • Birtch R.L.
        • Olatunbosun O.A.
        • Pierson R.A.
        Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use.
        Contraception. 2006; 73: 235-243
        • Legro R.S.
        • Pauli J.G.
        • Kunselman A.R.
        • et al.
        Effects of continuous versus cyclical oral contraception: a randomized controlled trial.
        J Clin Endocrinol Metab. 2008; 93: 420-429
        • Schlaff W.D.
        • Lynch A.M.
        • Hughes H.D.
        • Cedars M.I.
        • Smith D.L.
        Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression.
        Am J Obstet Gynecol. 2004; 190: 943-951
        • Archer D.F.
        • Maheux R.
        • DelConte A.
        • O'Brien F.B.
        • North American Levonorgestrel Study Group (NALSG)
        Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse).
        Am J Obstet Gynecol. 1999; 181: S39-S44
        • Guilbert E.
        • Boroditsky R.
        • Black A.
        • et al.
        Canadian Consensus Guideline on Continuous and Extended Hormonal Contraception, 2007.
        J Obstet Gynaecol Can. 2007; 29: S1-S32
        • Barnhart K.
        • Mirkin S.
        • Grubb G.
        • Constantine G.
        Return to fertility after cessation of a continuous oral contraceptive.
        Fertil Steril. 2009; 91: 1654-1656
        • Johnson J.V.
        • Grubb G.S.
        • Constantine G.D.
        Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 μg/ethinyl estradiol 20 μg.
        Contraception. 2007; 75: 23-26
        • Miller L.
        • Hughes J.P.
        Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial.
        Obstet Gynecol. 2003; 101: 653-661